BioCentury
ARTICLE | Company News

Asklepion Pharmaceuticals, Retrophin deal

March 23, 2015 7:00 AM UTC

Retrophin will acquire Cholbam cholic acid from Asklepion following FDA approval of the product to treat bile acid synthesis disorders due to single enzyme defects and as an adjuvant to treat peroxisomal disorders, including Zellweger spectrum disorders. Under a January deal, Retrophin gained the exclusive right to acquire the cholic acid capsules following FDA approval. Asklepion also received Priority Review voucher for Cholbam under FDA’s pediatric disease voucher program, which will transfer to Retrophin. Retrophin expects the deal to close and be able to launch Cholbam in as few as two to four weeks. Retrophin declined to disclose Cholbam’s price. ...